Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | GRM5 | P41594 | 6/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | CCR8 | P51685 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14182355 | 0.79 | MEN1 (0.31) | KMT2AMEN1RAB9AKDM4E | |
| SCHEMBL11712255 | 0.79 | RAB9A (0.55) | KMT2AMEN1RAB9AGRM5HSD17B10 | |
| SCHEMBL1861757 | 0.79 | RAB9A (0.55) | KMT2AMEN1RAB9AGRM5HSD17B10 | |
| SCHEMBL7294068 | 0.75 | MEN1 (0.31) | KMT2AMEN1RAB9AKDM4E | |
| SCHEMBL229747 | 0.75 | RAB9A (0.59) | KMT2AMEN1RAB9AGRM5HSD17B10 | |
| SCHEMBL30558522 | 0.73 | — | — | |
| SCHEMBL306134 | 0.73 | — | — | |
| SCHEMBL9588376 | 0.72 | KMT2A (0.52) | KMT2AMEN1RAB9AGRM5HSD17B10 | |
| SCHEMBL11707702 | 0.72 | MEN1 (0.43) | KMT2AMEN1RAB9AGRM5HSD17B10 | |
| SCHEMBL10138645 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101490038-B | Pyrimidine derivatives as ALK-5 inhibitors | NOVARTIS AG | 2013-08-14 | — | — | CN | disclosed |
| US-20080108600-A1 | Polycyclic Pyridines as Potassium Ion Channel Modulators | ICAGEN, INC. (US) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108600-A1 | Polycyclic Pyridines as Potassium Ion Channel Modulators | KCNJ2, KCNH2, KCNQ1 | KMT2A 563/4885MEN1 2428/4885RAB9A 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.